文献速递认知障碍与痴呆帕金森病与运动障碍神经肌肉病

脑脊液神经丝轻链蛋白在神经科诊断中的价值:系统综述与荟萃分析

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Neurol · 2019-01-01

多数神经疾病中cNfL高于健康对照,在认知受损的HIV阳性个体、肌萎缩侧索硬化、额颞叶痴呆和亨廷顿病中最高。cNfL随年龄增长,部分诊断中男性更高,有助于区分额颞叶痴呆与阿尔茨海默病、帕金森病与非典型帕金森综合征。

要点

  • cNfL在多数神经疾病中升高,最高见于iHIV、ALS、FTD和亨廷顿病。
  • cNfL随年龄增长,部分诊断中男性高于女性,可能需要年龄和性别特异性参考值。
  • cNfL有助于区分FTD与AD、PD与非典型帕金森综合征。

核心结论

  • cNfL可作为神经轴索损伤的生物标志物,可能需要年龄、性别和疾病特异性参考值。
  • cNfL有潜力辅助区分FTD与AD以及PD与非典型帕金森综合征。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed 2006年1月1日至2016年1月1日发表的文献。
  • 纳入报告腰穿脑脊液NfL水平(使用市售免疫分析)及年龄和性别的研究。
  • 使用广义线性混合效应模型估计年龄、性别和诊断对对数转换NfL水平的固定效应,以原队列为随机截距。

主要发现

  • 多数神经疾病中cNfL高于健康对照。
  • cNfL最高见于认知受损的HIV阳性个体、肌萎缩侧索硬化、额颞叶痴呆和亨廷顿病。
  • 在33.3%的诊断(包括健康对照、多发性硬化、阿尔茨海默病和帕金森病)中,男性cNfL高于女性。
  • cNfL随年龄增长,在健康对照中关联最强。
  • 多数临床相似诊断间cNfL存在重叠,但FTD和iHIV与其他痴呆分离,PD与非典型帕金森综合征分离。

关键数值与推荐

  • cNfL在认知受损的HIV阳性个体、肌萎缩侧索硬化、额颞叶痴呆和亨廷顿病中最高。
  • 33.3%的诊断中男性cNfL高于女性,包括健康对照、多发性硬化、阿尔茨海默病和帕金森病。
  • cNfL随年龄增长,健康对照中关联最强。
  • FTD和iHIV的cNfL与其他痴呆分离,PD与非典型帕金森综合征分离。

临床怎么用

  • cNfL可作为神经轴索损伤的生物标志物用于临床评估。
  • 解读cNfL时应考虑年龄和性别,必要时使用特异性参考值。
  • cNfL可辅助区分FTD与AD以及PD与非典型帕金森综合征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a number of neurological conditions compared with healthy controls (HC) and is a candidate biomarker for neuroaxonal damage. The influence of age and sex is largely unknown, and levels across neurological disorders have not been compared systematically to date. OBJECTIVES: To assess the associations of age, sex, and diagnosis with NfL in CSF (cNfL) and to evaluate its potential in discriminating clinically similar conditions. DATA SOURCES: PubMed was searched for studies published between January 1, 2006, and January 1, 2016, reporting cNfL levels (using the search terms neurofilament light and cerebrospinal fluid) in neurological or psychiatric conditions and/or in HC. STUDY SELECTION: Studies reporting NfL levels measured in lumbar CSF using a commercially available immunoassay, as well as age and sex. DATA EXTRACTION AND SYNTHESIS: Individual-level data were requested from study authors. Generalized linear mixed-effects models were used to estimate the fixed effects of age, sex, and diagnosis on log-transformed NfL levels, with cohort of origin modeled as a random intercept. MAIN OUTCOME AND MEASURE: The cNfL levels adjusted for age and sex across diagnoses. RESULTS: Data were collected for 10 059 individuals (mean [SD] age, 59.7 [18.8] years; 54.1% female). Thirty-five diagnoses were identified, including inflammatory diseases of the central nervous system (n = 2795), dementias and predementia stages (n = 4284), parkinsonian disorders (n = 984), and HC (n = 1332). The cNfL was elevated compared with HC in a majority of neurological conditions studied. Highest levels were observed in cognitively impaired HIV-positive individuals (iHIV), amyotrophic lateral sclerosis, frontotemporal dementia (FTD), and Huntington disease. In 33.3% of diagnoses, including HC, multiple sclerosis, Alzheimer disease (AD), and Parkinson disease (PD), cNfL was higher in men than women. The cNfL increased with age in HC and a majority of neurological conditions, although the association was strongest in HC. The cNfL overlapped in most clinically similar diagnoses except for FTD and iHIV, which segregated from other dementias, and PD, which segregated from atypical parkinsonian syndromes. CONCLUSIONS AND RELEVANCE: These data support the use of cNfL as a biomarker of neuroaxonal damage and indicate that age-specific and sex-specific (and in some cases disease-specific) reference values may be needed. The cNfL has potential to assist the differentiation of FTD from AD and PD from atypical parkinsonian syndromes.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Bridel C, van Wieringen WN, Zetterberg H, et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol. 2019. PMID: 31206160. doi:10.1001/jamaneurol.2019.1534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。